OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

Patients with advanced non-small cell lung cancer (NSCLC) and brain metastases have high unmet needs and could benefit from checkpoint inhibitors. In the randomized phase 3 CheckMate 9LA trial (NCT03215706), first-line nivolumab (NIVO) + ipilimumab (IPI) combined with chemotherapy (chemo) significantly improved overall survival (OS; primary endpoint) versus chemo alone in patients with advanced NSCLC. Clinical benefit was observed regardless of programmed death ligand 1 expression or histology. Here we report a post hoc analysis of efficacy and safety outcomes in patients with and without baseline (BL) brain metastases.